

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



深圳市海王英特龍生物技術股份有限公司
SHENZHEN NEPTUNUS INTERLONG BIO-TECHNIQUE COMPANY LIMITED*
(a joint stock limited company incorporated in the People's Republic of China)
(Stock Code: 8329)

**CHANGE OF FINANCIAL CONTROLLER AND BOARD SECRETARY AND
PROPOSED CHANGE OF COMPANY SECRETARY AND
AUTHORISED REPRESENTATIVE**

The board (the “**Board**”) of directors (the “**Directors**”) of Shenzhen Neptunus Interlong Bio-technique Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that, Ms. Mu Ling Xia (慕凌霞, “**Ms. Mu**”) was appointed as an executive director and vice general manager of Fuzhou Neptunus Fuyao Pharmaceutical Company Limited (福州海王福藥製藥有限公司), a major subsidiary of the Company, due to operational needs of the Group. In order to focus on her duties for the new positions, Ms. Mu has tendered her resignation to the Board as the vice general manager of the Company (the “**Vice General Manager**”), the company secretary of the Company (the “**Company Secretary**”), the Board secretary of the Company (the “**Board Secretary**”), the financial controller of the Company (the “**Financial Controller**”) and the authorised representative of the Company (the “**Authorised Representative**”), in which her resignation as the Vice General Manager, the Board Secretary and the Financial Controller is effective from 13 May 2020, and her resignation as the Company Secretary and the Authorised Representative will be effective from the approval date of appointment of Mr. Huang Jian Bo (黃劍波, “**Mr. Huang**”), the Vice General Manager, as the new Company Secretary and Authorised Representative which is subject to the approval of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Ms. Mu has confirmed that she has no disagreement with the Board and there are no other matters in relation to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company. The Board is also not aware of any such matters in relation to the resignation of Ms. Mu that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

During her tenure as the Vice General Manager, the Company Secretary, the Board Secretary, the Financial Controller and the Authorised Representative, Ms. Mu performed her duties diligently. The Board would like to highly appraise and express its gratitude to Ms. Mu for her valuable contributions to the Company during her tenure of office with the Company.

The Board is also pleased to announce that Mr. Huang, the Vice General Manager, has been appointed in place of Ms. Mu as the Company Secretary, the Board Secretary, the Financial Controller and the Authorised Representative in which his appointment as the Board Secretary and the Financial Controller is effective from 13 May 2020, and his appointment as the Company Secretary and the Authorised Representative will be subject to the approval of the Stock Exchange.

Set out below is the biography of Mr. Huang:

Mr. Huang Jian Bo, aged 44, graduated from Hunan University with a bachelor's degree in economics and majoring in finance and is a member of the Chinese Institute of Certified Public Accountants. Mr Huang has worked in the Company during the period from February 2003 to April 2016, and served as the Company's chief financial officer, joint company secretary, secretary to the board of directors and authorised representative. He rejoined the Company on 24 April 2020 and is currently the Vice General Manager. Mr. Huang was the financial controller of each of Anhui Jiuhua Huayuan Pharmaceutical Co., Ltd. (安徽九華華源藥業有限公司) and Shenzhen Ainengsen Technology Co., Ltd. (深圳愛能森科技有限公司). He has extensive experience in listing operations, financial management and investment management. Mr. Huang is also a candidate of executive Director for election at the forthcoming Annual General Meeting of the Company to be held on 19 June 2020.

By Order of the Board
Shenzhen Neptunus Interlong Bio-technique Company Limited*
Zhang Feng
Chairman

Shenzhen, PRC, 13 May 2020

As at the date of this announcement, the executive Directors are Mr. Zhang Feng and Mr. Xu Yan He; the non-executive Directors are Mr. Liu Zhan Jun, Ms. Yu Lin, Mr. Song Ting Jiu and Mr. Zhao Wen Liang; and the independent non-executive Directors are Mr. Yick Wing Fat, Simon, Mr. Poon Ka Yeung and Mr. Zhang Jian Zhou.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material aspects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Company Announcements" page of the GEM website at www.hkgem.com for at least 7 days from its date of publication and on the Company's website at www.interlong.com.

* For identification purpose only